Hematopoietic Capacity and Exceptional Survival: The Leiden Longevity Study
Article first published online: 15 SEP 2008
© 2008, Copyright the Authors. Journal compilation © 2008, The American Geriatrics Society
Journal of the American Geriatrics Society
Volume 56, Issue 11, pages 2009–2013, November 2008
How to Cite
Willems, J. M., Trompet, S., Eline Slagboom, P., De Craen, A. J.M. and Westendorp, R. G.J. (2008), Hematopoietic Capacity and Exceptional Survival: The Leiden Longevity Study. Journal of the American Geriatrics Society, 56: 2009–2013. doi: 10.1111/j.1532-5415.2008.01933.x
- Issue published online: 3 NOV 2008
- Article first published online: 15 SEP 2008
- hematopoietic capacity;
OBJECTIVES: To assess whether familial longevity can be attributed to sustained hematopoietic capacity.
DESIGN: Prospective follow-up study of two independent population-based cohorts.
SETTING: The Leiden Longevity Study and the Leiden 85-plus Study.
PARTICIPANTS: From the Leiden Longevity Study, 1,001 nonagenarians with familial longevity were included. As age-matched controls, 260 nonagenarians without familial longevity were used from the Leiden 85-plus Study.
MEASUREMENTS: Hemoglobin, leukocytes, and thrombocytes were measured for all subjects with and without familial longevity. Standardized mortality ratios, linear regression, and left-censored Cox regression were used for statistical analysis.
RESULTS: Mortality in nonagenarians with familial longevity was 28% lower than in nonagenarians from the general population (standardized mortality ratio=0.72, 95% confidence interval (CI)=0.65–0.79, P<.001). No differences were found between hemoglobin, leukocyte, and thrombocyte count in nonagenarians with and without familial longevity (all P>.30). Nonagenarians with familial longevity had greater mortality risk when anemia was present (sex-adjusted hazard ratio=1.71, 95% CI 1.41–2.07, P<.001). No relationship was found between leukocytes, thrombocytes, and mortality in either study group (all P>.20).
CONCLUSION: Hematopoietic capacity cannot explain the significantly better survival of nonagenarians with familial longevity, but in those with familial longevity, anemia may contribute to mortality.